TSW
GBT

Thompson Siegel & Walmsley’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Thompson Siegel & Walmsley’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-6,400
Closed -$148K – 921
2016
Q3 		$148K Buy
+6,400
New +$122K ﹤0.01% 418

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Thompson Siegel & Walmsley's GBT Position: Q4 2016 in Review

Thompson Siegel & Walmsley sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2016, closing a stake of 6,400 shares — an estimated $148K sold.

Thompson Siegel & Walmsley first reported a position in GBT in Q3 2016 and held it in 1 quarter. The position peaked at $148K in Q3 2016. 96 funds tracked by Wall St. Rank hold GBT as of Q4 2016.

  • Thompson Siegel & Walmsley reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 6,400 Global Blood Therapeutics, Inc. shares in Q4 2016, an estimated $148K.
  • Thompson Siegel & Walmsley first reported a position in Global Blood Therapeutics, Inc. in Q3 2016 and held it in 1 quarter.
  • Thompson Siegel & Walmsley's Global Blood Therapeutics, Inc. position peaked at $148K in Q3 2016.
  • 96 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2016.

Based on Thompson Siegel & Walmsley's 13F filing for Q4 2016, filed 13 Feb 2017.